Tags

Type your tag names separated by a space and hit enter

Pharmacologicaltreatment of COVID-19: lights and shadows.
Drugs Context. 2020; 9DC

Abstract

At the end of December 2019, a novel coronavirus, the severe acute respiratory syndrome coronavirus 2, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China and then the entire world, forcing the World Health Organization to make the assessment that the coronavirus disease (COVID-19) can be characterized as a pandemic, the first ever caused by a coronavirus. To date, clinical evidence and guidelines based on reliable data and randomized clinical trials for the treatment of COVID-19 are lacking. In the absence of definitive management protocols, many treatments for COVID-19 are currently being evaluated and tested worldwide. Some of these options were soon abandoned due to ineffectiveness, while others showed promising results. The basic treatments are mainly represented by antiviral drugs, even if the evidence is not satisfactory. Among the antivirals, the most promising appears to be remdesivir. Corticosteroids and tocilizumab seem to guarantee positive results in selected patients so far, although the timing of starting therapy and the most appropriate therapeutic schemes remain to be clarified. Efficacy of the other drugs is still uncertain, and they are currently used as a cocktail of treatments in the absence of definitive guidelines. What will represent the real solution to the enormous problem taking place worldwide is the identification of a safe and effective vaccine, for which enormous efforts and investments are underway.

Authors+Show Affiliations

Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy.University of Rome "La Sapienza," Rome, Italy.Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy.Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy.Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32499832

Citation

Menzella, Francesco, et al. "Pharmacologicaltreatment of COVID-19: Lights and Shadows." Drugs in Context, vol. 9, 2020.
Menzella F, Biava M, Barbieri C, et al. Pharmacologicaltreatment of COVID-19: lights and shadows. Drugs Context. 2020;9.
Menzella, F., Biava, M., Barbieri, C., Livrieri, F., & Facciolongo, N. (2020). Pharmacologicaltreatment of COVID-19: lights and shadows. Drugs in Context, 9. https://doi.org/10.7573/dic.2020-4-6
Menzella F, et al. Pharmacologicaltreatment of COVID-19: Lights and Shadows. Drugs Context. 2020;9 PubMed PMID: 32499832.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacologicaltreatment of COVID-19: lights and shadows. AU - Menzella,Francesco, AU - Biava,Mirella, AU - Barbieri,Chiara, AU - Livrieri,Francesco, AU - Facciolongo,Nicola, Y1 - 2020/05/19/ PY - 2020/04/13/received PY - 2020/04/30/revised PY - 2020/04/30/accepted PY - 2020/6/6/entrez PY - 2020/6/6/pubmed PY - 2020/6/6/medline KW - antivirals KW - biologics KW - coronavirus KW - corticosteroids KW - pneumonia KW - severe acute respiratory syndrome JF - Drugs in context JO - Drugs Context VL - 9 N2 - At the end of December 2019, a novel coronavirus, the severe acute respiratory syndrome coronavirus 2, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China and then the entire world, forcing the World Health Organization to make the assessment that the coronavirus disease (COVID-19) can be characterized as a pandemic, the first ever caused by a coronavirus. To date, clinical evidence and guidelines based on reliable data and randomized clinical trials for the treatment of COVID-19 are lacking. In the absence of definitive management protocols, many treatments for COVID-19 are currently being evaluated and tested worldwide. Some of these options were soon abandoned due to ineffectiveness, while others showed promising results. The basic treatments are mainly represented by antiviral drugs, even if the evidence is not satisfactory. Among the antivirals, the most promising appears to be remdesivir. Corticosteroids and tocilizumab seem to guarantee positive results in selected patients so far, although the timing of starting therapy and the most appropriate therapeutic schemes remain to be clarified. Efficacy of the other drugs is still uncertain, and they are currently used as a cocktail of treatments in the absence of definitive guidelines. What will represent the real solution to the enormous problem taking place worldwide is the identification of a safe and effective vaccine, for which enormous efforts and investments are underway. SN - 1745-1981 UR - https://www.unboundmedicine.com/medline/citation/32499832/Pharmacologicaltreatment_of_COVID_19:_lights_and_shadows_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.